Carisma Therapeutics Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Loss on disposal of property and equipment
Stock-based compensation expense
Change in fair value of contingent consideration
Intangibles impairment charge
Net amortization of discounts and premiums on marketable securities
Reduction in the operating right of use assets
Amortization of debt discount
Change in fair value of derivative liability
Accretion on marketable securities
Write-off of property and equipment
Realized gain on marketable securities
Non-cash interest expense
Loss on sale of equipment
Gain on sale of sale-leaseback
Changes in operating assets and liabilities:
Accounts receivable (net)
Other receivables
Prepaid expenses and other assets
Long term prepaid expenses
Other assets
Accounts payable
Accrued expenses
Deferred revenue
Operating lease liabilities
Other long term liabilities
Net cash used in operating activities
Purchase of marketable securities
Proceeds from maturity of marketable securities
Disposal of equipment
Purchases of equipment

Cash flows from investing activities:
Purchase of marketable securities
Proceeds from the sale of marketable securities
Purchases of property and equipment
Net cash (used in) provided by investing activities
Proceeds from issuance of common stock and common stock warrants, net of issuance costs

Cash flows from financing activities:
Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization
Payment of reverse recapitalization finance costs
Proceeds from the issuance of common stock in pre-closing financing
Payment of principal related to finance lease liabilities
Proceeds from failed sale-leaseback arrangement
Payment of finance liability from failed sale-leaseback arrangements
Payment of deferred financing costs
Proceeds from issuance of convertible promissory note
Proceeds from the exercise of stock options
Proceeds from exercises of common stock warrants
Proceeds from sale of common stock pursuant to ESPP
Sale of common stock under Open Market Sales Agreement, net of issuance costs
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of the year
Cash and cash equivalents at end of the year
Cash and cash equivalents
Short term restricted cash
Long term restricted cash
Supplemental disclosures of cash flow information:
Right-of-use assets related to the adoption of ASC 842
Cash paid for interest
Supplemental disclosure of non-cash financing and investing activities:
Cash paid for amounts included in the measurement of lease liabilities
Conversion of convertible preferred stock and non-controlling interests upon Merger
Conversion of convertible promissory note, accrued interest and derivative liability upon Merger
Unrealized gain on marketable securities
Deferred financing costs in accrued expenses
Reclassification of deferred financing costs to additional paid-in-capital
Right-of-use assets obtained in exchange for new financing lease liabilities
Allocation of debt proceeds to derivative liability
Right-of-use assets obtained in exchange for new operating lease liabilities
Deemed Dividend on adjustment of exercise price on certain warrants
Modification of operating lease right-of-use asset and operating lease liabilities
Disposal of property and equipment in exchange for reduction in financing lease liability

Comments